Radient Pharmaceuticals Corporation fka RXPC

[guardiangel]

RADIENT RESTRUCTURED BY A PLANNED REVERSE MERGER

Checkout my next post on how Provista Diagnostics Inc. will reverse merge with Radient Pharmaceuticals Corp according to the Letter of intent...LOI of 2010..After the merger we will be dropping the Radient name ..It will be replaced with Provista you understand...

Keep on hitting these previous I-Hub Links..There is a surprise at the end you understand..It is the "Wolf Code"..Here is the latest..


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=117137077



This is why Provista Diagnostics Inc. wants the Radient Pharmaceutical shell and AMDL Diagnostics Inc. will be spun off to Uni-Pharma. imo E.F.Wolf

Re: Radient Restructured By A Planned Reverse Merger

DC.... Here are the Two Trademarks for the CIT IP...........Is the cat out of the hat or the hat out of the cat you understand..... Look for late October for the two Trademarks to be registered....I know curiosity killed the cat...Why did they drop Klarifyi.....Or did they..It is still alive...It would be abandoned in Late October 2015 if they decide to abandon Klarifyi....


http://www.trademarkia.com/correspondent-joseph-r-meaney-2-514743



Word Mark CLARENIDI

Status686 - Published For Opposition

Status Date2015-08-18

Filing Date2015-03-30



Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, cancers and genetic diseases; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing;


Providing reagent sample testing and diagnostic services for others in the fields of science and research related thereto; Scientific laboratory services; Scientific study and research in the field(s) of molecular diagnostics, cancer biology, genetics and genetic engineering..Medical services, namely,providing cancer screening services, medical testing for diagnostic

or treatment purposes in the field of cancer,

medical diagnosis of cancer; Medical testing for diagnostic or treatment purposes; Medical testing for diagnostic or treatment purposes in the field of genetic diseases and cancer

Should be approved and registered by October 27, 2015.....

2015-08-18 OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

https://trademarks.justia.com/865/81/clarenidi-86581669.html

Senepea and Clarendi are the same and will be registered by Late October 2015..One must be for domestic and the other international...

Word Mark SENEPEA

Status686 - Published For Opposition

Status Date2015-08-18

Filing Date2015-03-30

https://trademarks.justia.com/865/81/senepea-86581643.html

YI ahoooooooooooooooooooooooooooooooooooooooooo

Why did they drop this one..It is the one they were going to use at a convention...lol Thay only needed two you understand.....

Word Mark KLARIFYI

Status641 - Non-Final Action - Mailed

Status Date2015-07-10

Filing Date2015-03-30

2015-07-10 NON-FINAL ACTION WRITTEN
2015-07-10 NON-FINAL ACTION E-MAILED
2015-07-10 NOTIFICATION OF NON-FINAL ACTION E-MAILED


https://trademarks.justia.com/865/81/klarifyi-86581663.html




Word Mark PDX
Status602 - Abandoned-Failure To Respond Or Late Response
Status Date2014-01-14
Filing Date2013-03-01


2013-06-18 NON-FINAL ACTION WRITTEN
2013-06-18 NON-FINAL ACTION E-MAILED
2013-06-18 NOTIFICATION OF NON-FINAL ACTION E-MAILED
2014-01-14 ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
2014-01-14 ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND

RADIENT RESTRUCTURED BY A PLANNED REVERSE MERGER

http://www.dancewithshadows.com/pillscribe/jaiva-to-trial-radients-new-cancer-vaccine-combination-immunogene-therapy-technology-in-india/

"Also, the separate capitalization and public listing of NuVax, a recently formed partnership with Jaiva Technologies, involving RPC’s Combined Immunogene Therapy (CIT) patented technology, may take a little longer, since NuVax may first seek to complete Phase 11 clinical trials."


RPC has two other “assets” that are considered “non-core:” Jade Pharmaceuticals (98% owned), one of the leading providers of domperidone, used to prevent nausea and vomiting caused by chemotherapy and other medications’ and NuVax, a newly formed partnership, aimed at commercializing RPC’s patented CIT combination gene therapy that is designed to build the body’s immune system and destroy cancer cells.

Jade was deconsolidated in 2009, and is moving toward a prospective industry acquisition and a U.S.-based listing by midyear. Much has been disclosed about the proposed “capitalization and a listing event.” Because of these disclosures, and the deconsolidation, this report will not attempt to review operations and options.

NuVax may want to complete Phase 11 clinical trials before the partnership explores “capitalization and a listing event.” Again, this report will not attempt to summarize developments.




http://www.cpreports.com/2010/12/06/len-bogner-radient-pharmaceuticals-rpc-dec-28-2010/



"Also, the separate capitalization and public listing of NuVax, a recently formed partnership with Jaiva Technologies, involving RPC’s Combined Immunogene Therapy (CIT) patented technology, may take a little longer, since NuVax may first seek to complete Phase 11 clinical trials."


RPC has two other “assets” that are considered “non-core:” Jade Pharmaceuticals (98% owned), one of the leading providers of domperidone, used to prevent nausea and vomiting caused by chemotherapy and other medications’ and NuVax, a newly formed partnership, aimed at commercializing RPC’s patented CIT combination gene therapy that is designed to build the body’s immune system and destroy cancer cells.

Jade was deconsolidated in 2009, and is moving toward a prospective industry acquisition and a U.S.-based listing by midyear. Much has been disclosed about the proposed “capitalization and a listing event.” Because of these disclosures, and the deconsolidation, this report will not attempt to review operations and options.

NuVax may want to complete Phase 11 clinical trials before the partnership explores “capitalization and a listing event.” Again, this report will not attempt to summarize developments.




http://www.cpreports.com/2010/12/06/len-bogner-radient-pharmaceuticals-rpc-dec-28-2010/



"Also, the separate capitalization and public listing of NuVax, a recently formed partnership with Jaiva Technologies, involving RPC’s Combined Immunogene Therapy (CIT) patented technology, may take a little longer, since NuVax may first seek to complete Phase 11 clinical trials."


RPC has two other “assets” that are considered “non-core:” Jade Pharmaceuticals (98% owned), one of the leading providers of domperidone, used to prevent nausea and vomiting caused by chemotherapy and other medications’ and NuVax, a newly formed partnership, aimed at commercializing RPC’s patented CIT combination gene therapy that is designed to build the body’s immune system and destroy cancer cells.

Jade was deconsolidated in 2009, and is moving toward a prospective industry acquisition and a U.S.-based listing by midyear. Much has been disclosed about the proposed “capitalization and a listing event.” Because of these disclosures, and the deconsolidation, this report will not attempt to review operations and options.

NuVax may want to complete Phase 11 clinical trials before the partnership explores “capitalization and a listing event.” Again, this report will not attempt to summarize developments.




http://www.cpreports.com/2010/12/06/len-bogner-radient-pharmaceuticals-rpc-dec-28-2010/

This was the mission before provista DX came along..The IP's that have been transferred to the Wholly owned subsidiary have been DR-70 and transferred to AMDL Diagnostics Inc. that was formed as stated below..CIT remains in the shell of Radient...Who are the financiers and corporate partners as mentioned below...




" It is our intention to form a new wholly-owned subsidiary for our Cancer Therapeutics division, to which we will transfer all of our patents relating to, regulatory approvals for, and all of our other interests in and to our CIT technology. We anticipate that the transfer of our CIT technology will be completed in the second quarter of 2009. By transferring our CIT technology, we are hopeful that we can find financing and/or a corporate partner to further exploit the CIT Technology."

http://www.wikinvest.com/stock/AMDL_(ADL)/Combination_Immunogene_Therapy